Loading stock…

Stryker Corporation (SYK) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Stryker Corporation

SYKMarket cap $106BPrice $275.4

Country🇺🇸United States

SectorHealthcare

IndustryHealthcare Equipment

Makes surgical instruments, implants, and medical devices that help millions walk again after joint replacements. Controls nearly 40% of the global hip and knee implant market worth $20 billion annually.

In Bastion Portfolios?

52W Return-26%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+11%7

Revenue Forecast

Rev CAGR (1y)+8%6

Rev CAGR (3y)+8%6

Rev CAGR (5y)+8%7

Earnings Forecast

EPS Growth Y+1+80%10

EPS Growth Y+2+11%7

EPS Growth Y+3+11%7

Quality

Margins

EBIT Margin24%8

Net Income Margin14%7

Free Cash Flow Margin18%8

Debt

Net Debt/EBITDA1.65

Efficiency

ROE17%7

ROA8%8

Earnings Stability88

GEAR+VERY STRONG88

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)175

P/E Ratio (Forward 3y)155

P/BV4.44

EV Multiples

EV/EBITDA Fwd154

EV/EBIT Fwd165

Yield

Free Cash Flow Yield4.5%6

Dividend Yield1.3%4

Momentum

Short term

1 month return-0%8

3 month return-15%2

YTD return-21%2

Mid term

Price vs 52wHigh71%4

1 year return-26%2

Long term

3 year return+7%3

5 year return+10%4

Risk Shield

Price Risk

Beta0.67

Volatility30%7

Free Cash Flow

Free Cash Flow Margin18%8

Free Cash Flow Yield4.5%6

Quality

ROCE15%8

Earnings Stability88

Net Debt/EBITDA1.65

02Growth

Is it actually growing, and how fast?

SYKStryker

Revenue FY25$25.1B

GROWTH RATING↗

AVERAGE64 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+11%7

Revenue, next 1Y+8%6

Revenue, next 3Y, CAGR+8%6

Revenue, next 5Y, CAGR+8%7

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+80%10

EPS growth, FY27E+11%7

EPS growth, FY28E+11%7

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 11%/yr over the last 3 years, ahead of 60% of companies worldwide.7/10

The runway holds up: revenue is set to grow 8%/yr over five years.7/10

Earnings are set to grow in step with sales (EPS about 11%/yr vs revenue 8%/yr).

WATCH

A mid-pack grower, ahead of 64% of companies worldwide.

Revenue is set to grow 8%/yr over the next 3 years, a little ahead of the market.6/10

Revenue grew 11%/yr over the last 3 years and is set to keep growing around 8%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

WEAK21 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-0%8

3-month return-15%2

YTD return-21%2

MID & LONG-TERM▾SCORE

% of 52-week high71%4

1-year return-26%2

3-year return+7%3

5-year return+10%4

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (+0%).

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+6.7% over three years and +10% over five), behind 60% of the market.

It's down 26% over the past year, now 29% below its 52-week high. That is lagging the market.

The stock is underperforming over three months (-15%) and so far this year (-21%).

BOTTOM LINE

Falling Knife

Returns rank poorly over both the short and long run, and the price is still falling. Momentum is firmly negative — catching this is a bet against the tape, not with it. Wait for a base to form. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Stryker. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

SYKStryker

Revenue FY25$25.1B

GROWTH RATING↗

AVERAGE64 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+11%7

Revenue, next 1Y+8%6

Revenue, next 3Y, CAGR+8%6

Revenue, next 5Y, CAGR+8%7

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+80%10

EPS growth, FY27E+11%7

EPS growth, FY28E+11%7

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 11%/yr over the last 3 years, ahead of 60% of companies worldwide.7/10

The runway holds up: revenue is set to grow 8%/yr over five years.7/10

Earnings are set to grow in step with sales (EPS about 11%/yr vs revenue 8%/yr).

WATCH

A mid-pack grower, ahead of 64% of companies worldwide.

Revenue is set to grow 8%/yr over the next 3 years, a little ahead of the market.6/10

Revenue grew 11%/yr over the last 3 years and is set to keep growing around 8%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

WEAK21 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-0%8

3-month return-15%2

YTD return-21%2

MID & LONG-TERM▾SCORE

% of 52-week high71%4

1-year return-26%2

3-year return+7%3

5-year return+10%4

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (+0%).

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+6.7% over three years and +10% over five), behind 60% of the market.

It's down 26% over the past year, now 29% below its 52-week high. That is lagging the market.

The stock is underperforming over three months (-15%) and so far this year (-21%).

BOTTOM LINE

Falling Knife

04Value

Are you paying a fair price for it?

Stop guessing on Stryker. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community